News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients

Aug 27, 2018
Dave Levitan
Article

A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important.

A small study characterized patients with pheochromocytoma or paraganglioma (PCC/PGL) associated with the hereditary syndrome neurofibromatosis type 1 (NF1), and highlights how screening for these malignancies, especially prior to surgery, could be important.

There are currently recommendations to screen for PCC/PGL in patients with several other hereditary mutations, but not for NF1. “For rare conditions like PCC/PGL, often there is minimal evidence to guide the development of screening protocols,” wrote study authors led by Tobias Else, MD, of the University of Michigan in Ann Arbor. “The value in screening at-risk gene mutation carriers for PCC/PGL is the opportunity to decrease morbidity and mortality through early disease detection and treatment.”

NF1 is a relatively common condition, occurring in 1 in 3,000 live births; between 5% and 7% of those with NF1 will develop PCC/PGL in their lifetime. The authors conducted a chart review of 17 patients with NF1-associated PCC/PGL in order to better characterize the phenotype of this condition. The results were published in Clinical Diabetes and Endocrinology.

Nine of the 17 patients were male, and the average age of diagnosis was 41 years. Eight of the cases were discovered incidentally on imaging studies done for other reasons, and nine were identified during workup of hypertension or other symptoms.

Nine patients had hypertension, and four had tachycardia (five had unknown status); two patients had both hypertension and tachycardia. All but one patient, whose status was unknown, had elevated plasma or urine catecholamines or metanephrine; 10 patients had elevations in both metanephrines and in normetanephrines.

Six patients experienced at least one cardiovascular crisis, which the authors wrote was “the most notable finding in our study.” These included cardiac arrest, myocardial infarction, intraoperative labile blood pressures, and extreme tachycardia. Three of these episodes occurred during an elective surgery to remove a neurofibroma.

The average size of the PCC/PGL tumor was 3.9 cm; of 20 total tumors, 18 were located in the adrenal gland, while one was an extra-adrenal abdominal PGL and one was a head and neck PGL. There were three patients with bilateral PCCs, two of which were synchronous and one of which was metachronous, occurring 6 years after treatment of the original tumor.

Two patients had a local disease recurrence following resection, and two had confirmed metastatic disease (one other patient had possible metastatic disease but was lost to follow-up).

“These data, particularly considering the high frequency of elective surgical procedures for patients with NF1, highlight the importance of PCC/PGL screening in the NF1 population, especially prior to situations that may trigger a crisis such as surgery, or pregnancy, labor, and delivery,” the authors wrote. “We suggest consideration of screening adults with NF1 for PCC/PGL with plasma or urine free fractionated metanephrines every 1–2 years starting at age 18, especially in any NF1 patient with hypertension or tachycardia, and most importantly prior to any surgical procedures and pregnancy or delivery.”

Related Videos
Kelley Lauren Coffman, MD
Kelley Lauren Coffman, MD
Kelley Lauren Coffman, MD
Satya Das, MD, MSCI
Kelley Lauren Coffman, MD
Satya Das, MD, MSCI
Kelley Lauren Coffman, MD
Satya Das, MD, MSCI
Related Content

Cabozantinib Efficacy Leads to Unblinding of Advanced Pancreatic NETs Trial

August 28th 2023

DLL3-Targeting T-cell Engager May be Safe/Effective in SCLC and NEC

June 4th 2023

Study Supports FOLFIRI as Standard for Second-Line Neuroendocrine Carcinoma

April 19th 2023

SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors

February 9th 2023

New Drug Application Complete for Surufatinib to Treat Pancreatic/Extra-Pancreatic NETs

May 3rd 2021

Adavosertib Plus Irinotecan Combination Met Efficacy End Point for Pediatric Neuroblastoma

April 13th 2021

Cabozantinib Efficacy Leads to Unblinding of Advanced Pancreatic NETs Trial

August 28th 2023

DLL3-Targeting T-cell Engager May be Safe/Effective in SCLC and NEC

June 4th 2023

Study Supports FOLFIRI as Standard for Second-Line Neuroendocrine Carcinoma

April 19th 2023

SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors

February 9th 2023

New Drug Application Complete for Surufatinib to Treat Pancreatic/Extra-Pancreatic NETs

May 3rd 2021

Adavosertib Plus Irinotecan Combination Met Efficacy End Point for Pediatric Neuroblastoma

April 13th 2021

Cabozantinib Efficacy Leads to Unblinding of Advanced Pancreatic NETs Trial

August 28th 2023

DLL3-Targeting T-cell Engager May be Safe/Effective in SCLC and NEC

June 4th 2023

Study Supports FOLFIRI as Standard for Second-Line Neuroendocrine Carcinoma

April 19th 2023

SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors

February 9th 2023

New Drug Application Complete for Surufatinib to Treat Pancreatic/Extra-Pancreatic NETs

May 3rd 2021

Adavosertib Plus Irinotecan Combination Met Efficacy End Point for Pediatric Neuroblastoma

April 13th 2021
Related Content
Advertisement

The safety profile of cabozantinib as a treatment for patients with advanced pancreatic neuroendocrine tumors in the phase 3 CABINET trial is comparable with previous reports of the agent.

Cabozantinib Efficacy Leads to Unblinding of Advanced Pancreatic NETs Trial

August 28th 2023
Article

The safety profile of cabozantinib as a treatment for patients with advanced pancreatic neuroendocrine tumors in the phase 3 CABINET trial is comparable with previous reports of the agent.


Patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma experience early efficacy following treatment with BI 764532.

DLL3-Targeting T-cell Engager May be Safe/Effective in SCLC and NEC

June 4th 2023
Article

Patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma experience early efficacy following treatment with BI 764532.


The addition of bevacizumab to FOLFIRI does not appear to improve overall survival over FOLFIRI alone in patients with gastroenteropancreatic neuroendocrine carcinoma.

Study Supports FOLFIRI as Standard for Second-Line Neuroendocrine Carcinoma

April 19th 2023
Article

The addition of bevacizumab to FOLFIRI does not appear to improve overall survival over FOLFIRI alone in patients with gastroenteropancreatic neuroendocrine carcinoma.


Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.

SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors

February 9th 2023
Article

Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.


New Drug Application Complete for Surufatinib to Treat Pancreatic/Extra-Pancreatic NETs

New Drug Application Complete for Surufatinib to Treat Pancreatic/Extra-Pancreatic NETs

May 3rd 2021
Article

Rolling submission with the FDA for surufatinib treatment in patients with pancreatic and extra-pancreatic neoendocrume tumors was completed and an expanded access program for the drug is currently underway for patients in the United States.


Adavosertib Plus Irinotecan Combination Met Efficacy End Point for Pediatric Neuroblastoma

Adavosertib Plus Irinotecan Combination Met Efficacy End Point for Pediatric Neuroblastoma

April 13th 2021
Article

Data presented at the virtual AACR Annual Meeting 2021 showed that a phase 2 trial examining combination treatment with adavosertib plus irinotecan met its protocol-defined efficacy end point in a cohort of pediatric patients with neuroblastoma.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.